David Hallett - 15 May 2026 Form 4 Insider Report for RECURSION PHARMACEUTICALS, INC. (RXRX)

Reporting relationship: Chief Scientific Officer
Issuer ticker: RXRX
Reported as of: 15 May 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 19 May 2026, 17:54:56 UTC
Prior SEC filing: 19 Feb 2026
Source filing: View source filing
Reporting owner signature: /s/Jonathan Golightly, attorney-in-fact

Key filing fact

David Hallett filed Form 4 for RECURSION PHARMACEUTICALS, INC. (RXRX) on 19 May 2026.

Key facts

This page summarizes David Hallett's Form 4 filing for RECURSION PHARMACEUTICALS, INC. (RXRX).
1 reported transaction and 0 derivative rows are listed below.
Accepted by SEC: 19 May 2026, 17:54.

Change

Previous filing in this sequence was filed on 19 Feb 2026.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0002006495 Primary reporting owner

Hallett David

Relationship: Chief Scientific Officer
Address: C/O RECURSION PHARMACEUTICALS, 41 S. RIO GRANDE STREET, SALT LAKE CITY
Signature: /s/Jonathan Golightly, attorney-in-fact
Signature date: 18 May 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

RXRX transaction

Class A Common Stock

Tax liability

Transaction value
Shares: -26,657
Change %: -2.4%
Price: $3.04^*
Shares after: 1,070,494
Date: 15 May 2026
Ownership: Direct
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

Represents shares that have been withheld by the Issuer to satisfy its tax withholding and remittance obligations in connection with the net settlement of restricted stock units.